However, the amount of safety data available for the drug is still limited
News
Oxford Biomedica and VMIC announce collaboration
The five-year deal will see the parties work collaboratively to facilitate the manufacture of viral vector based vaccines
NHS patients given devices and apps for remote monitoring
The move is part of the NHS drive to give more people connected, personalised care in their own homes
AZ’ Calquence shows promise for COVID-19
Improved markers of inflammation and reduced oxygen requirements were seen in most patients
Imperial College London forms new social enterprise
VacEquity Global Health (VGH) has been established to accelerate low-cost COVID-19 vaccine
CV patients finding it harder to get treatment during pandemic
The BHF is calling on the government to address the issue or the backlog will continue to grow putting patients at risk of getting sicker
AZ ramps up supply capacity for COVID-19 vaccine
Agreements with CEPI and Gavi and the Serum Institute of India will bring vaccine to low and middle-income countries and beyond, the firm said
The Lancet retracts study linking hydroxychloroquine with deaths
The study linked the drug with higher death rates in patients with COVID-19
Lilly bags expanded EU approval for Taltz
Taltz has been granted an additional indication for the treatment of patients across the full axSpA spectrum
PharmaTimes talks to…Professor Saad Shakir
Professor Shakir, director of the Drug Safety Research Unit, explains the cytokine storm, a major killer in patients with severe COVID-19 infection
Biogen launches digital self-help tool to support mental health in MS
ACT MySelf, was developed by Biogen in collaboration with people living with MS, the MS Trust, a team of MS specialist nurses and an MS clinical psychologist
NICE publishes final guidance backing Teva’s Ajovy for migraine
One in seven UK adults is affected by migraine
AZ, Accent to develop therapies targeting RNA-modifying proteins
These proteins control various aspects of RNA biology and represent a new target for cancer treatment
Hydroxychloroquine fails as postexposure prophylaxis for COVID-19
However, the trial did have limitations, researchers note
EU nod for new metastatic colorectal cancer combination
Pierre Fabre’s Braftovi in combination with Erbitux is the first licensed therapy for a specific subset of colorectal cancer patients
